The clinical potential for koff-rate measurement in adoptive immunotherapy

Expert Review of Clinical Immunology

Volumn 9, Issue 12, 2013, Pages 1151-1153

  Nauerth, Magdalena ^a   Weissbrich, Bianca ^a   Busch, Dirk H ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b DZIF National Centre for Infection Research   (Germany)

Author keywords

Avidity threshold; Endogenous T cell repertoire; Immunotherapy; Optimal avidity; TCR engineering; TCR ligand koff rate assay; TCR pMHC binding

Indexed keywords

CD8 ANTIGEN; OVALBUMIN; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ALLOIMMUNITY; CELL INTERACTION; CELLULAR IMMUNITY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; HALF LIFE TIME; HUMAN; IMMUNOASSAY; IMMUNOLOGICAL PARAMETERS; K OFF RATE; LISTERIOSIS; MAJOR HISTOCOMPATIBILITY COMPLEX; REVIEW; T LYMPHOCYTE ACTIVATION; TARGET CELL;

ANIMALS; ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LIGANDS; PROTEIN BINDING; PROTEIN ENGINEERING; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84887930148     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2013.855609     Document Type: Review

References (19)

1. Stone JD, Chervin AS, Kranz DM. T-cell receptor binding affinities and kinetics: Impact on T-cell activity and specificity. Immunology 126(2), 165-176 (2009
2. Zehn D, Lee SY, Bevan MJ. Complete but curtailed T-cell response to very low-affinity antigen. Nature 458(7235), 211-214 (2009
3. Derby MA, Alexander-Miller MA, Tse R, Berzofsky JA. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J. Immunol. 166(3), 1690-1697 (2001
4. Knabel M, Franz TJ Schiemann M et al. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat. Med. 8(6), 631-637 (2002
5. Nauerth M, Weissbrich B Knall R et al. TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer. Sci. Transl. Med. 5(192), 192ra187 (2013
6. Hombrink P, Raz Y Kester MGD et al. Mixed functional characteristics correlating with TCR-ligand koff -rate of MHC-tetramer reactive T cells within the naive T-cell repertoire. Eur. J. Immunol. (2013
7. Buchholz VR, Flossdorf M Hensel I et al. Disparate individual fates compose robust CD8+ T cell immunity. Science 340(6132), 630-635 (2013
8. Stemberger C, Huster KM Koffler M et al. A single naive CD8+ T cell precursor can develop into diverse effector and memory subsets. Immunity 27(6), 985-997 (2007
9. Aleksic M, Dushek O Zhang H et al. Dependence of T cell antigen recognition on T cell receptor-peptide MHC confinement time. Immunity, 32(2), 163-174 (2010
10. Alam SM, Davies GM Lin CM et al. Qualitative and quantitative differences in T cell receptor binding of agonist and antagonist ligands. Immunity, 10(2), 227-237 (1999
11. Zhao Y, Bennett AD Zheng Z et al. High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J. Immunol. 179(9), 5845-5854 (2007
12. Robbins PF, Li YF, El-Gamil M et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J. Immunol. 180(9), 6116-6131 (2008
13. Holler PD, Chlewicki LK, Kranz DM. TCRs with high affinity for foreign pMHC show self-reactivity. Nat. Immunol. 4(1), 55-62 (2003
14. Irving M, Zoete V Hebeisen M et al. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J. Biol. Chem. 287(27), 23068-23078 (2012
15. Kalergis AM, Boucheron N, Doucey M-A et al. Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex. Nat. Immunol. 2(3), 229-234 (2001
16. Hebeisen M, Baitsch L Presotto D et al. SHP-1 phosphatase activity counteracts increased T cell receptor affinity. J. Clin. Invest. 123(3), 1044-1056 (2013
17. Robbins PF, Morgan RA Feldman SA et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29(7), 917-924 (2011
18. Linette GP, Stadtmauer EA Maus MV et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122(6), 863-871 (2013
19. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365(8), 725-733 (2011